JP2020532958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532958A5 JP2020532958A5 JP2020507679A JP2020507679A JP2020532958A5 JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5 JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5
- Authority
- JP
- Japan
- Prior art keywords
- ribonucleic acid
- acid compound
- cell
- compound according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 104
- 229920002477 rna polymer Polymers 0.000 claims description 84
- 210000004027 cell Anatomy 0.000 claims description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 16
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108091029810 SaRNA Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 239000012216 imaging agent Substances 0.000 claims description 8
- 229940078677 sarna Drugs 0.000 claims description 8
- 238000003384 imaging method Methods 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 102000000344 Sirtuin 1 Human genes 0.000 claims description 2
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000002923 metal particle Substances 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544220P | 2017-08-11 | 2017-08-11 | |
| US62/544,220 | 2017-08-11 | ||
| US201862671604P | 2018-05-15 | 2018-05-15 | |
| US62/671,604 | 2018-05-15 | ||
| PCT/US2018/046343 WO2019033051A1 (en) | 2017-08-11 | 2018-08-10 | RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532958A JP2020532958A (ja) | 2020-11-19 |
| JP2020532958A5 true JP2020532958A5 (enExample) | 2021-09-16 |
| JP7382919B2 JP7382919B2 (ja) | 2023-11-17 |
Family
ID=65271776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507679A Active JP7382919B2 (ja) | 2017-08-11 | 2018-08-10 | トランスフェリン受容体（ＴｆＲ）に対するＲＮＡアプタマー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11427826B2 (enExample) |
| EP (1) | EP3664814A4 (enExample) |
| JP (1) | JP7382919B2 (enExample) |
| KR (1) | KR20200068647A (enExample) |
| CN (2) | CN111542326B (enExample) |
| AU (1) | AU2018314236B2 (enExample) |
| CA (1) | CA3072575A1 (enExample) |
| WO (1) | WO2019033051A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020208361A1 (en) * | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| US20220396794A1 (en) | 2019-06-04 | 2022-12-15 | Apterna Limited | APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR) |
| GB202019692D0 (en) | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| CN118879700B (zh) * | 2024-07-18 | 2025-11-07 | 四川大学 | 具有sirt1基因靶向激活功能的框架核酸药物的制备及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| JP2006089471A (ja) | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| US20100209437A1 (en) | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| KR101589759B1 (ko) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ｃｄ３―입실론 결합 도메인 |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| PT2155783E (pt) | 2007-04-03 | 2013-11-07 | Amgen Res Munich Gmbh | Domínio de ligação específico inter-espécies |
| JP5142265B2 (ja) | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| WO2011071099A1 (ja) | 2009-12-10 | 2011-06-16 | 独立行政法人産業技術総合研究所 | 抗癌性抗モータリンペプチド抗体 |
| US8916534B2 (en) * | 2010-10-08 | 2014-12-23 | Mina Therapeutics Limited | Methods of inducing insulin production |
| CA2870288A1 (en) | 2012-04-10 | 2013-10-17 | John J. Rossi | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
| PL2953972T3 (pl) | 2013-02-05 | 2021-03-08 | Engmab Sàrl | Metoda wyboru przeciwciał przeciwko bcma |
| WO2014147559A1 (en) | 2013-03-18 | 2014-09-25 | University Of The Witwatersrand, Johannesburg | Cd7 receptor aptamers |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| SG11201508231UA (en) | 2013-04-19 | 2015-11-27 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity |
| EP3094737A4 (en) | 2014-01-15 | 2017-08-09 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
| US9605266B2 (en) | 2014-07-16 | 2017-03-28 | City Of Hope | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore |
| KR20170055474A (ko) | 2014-07-31 | 2017-05-19 | 아카데미아 시니카 | 길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용 |
| CN107106697B (zh) | 2014-10-15 | 2021-06-18 | 希望之城 | Pdgfr rna适体 |
| JP6661645B2 (ja) * | 2014-10-15 | 2020-03-11 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | トランスフェリン受容体（ｔｆｒ）に対するｒｎａアプタマー |
| EP3250930A1 (en) | 2015-01-27 | 2017-12-06 | Klinikum rechts der Isar der Technischen Universität München | Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids |
| JP6978317B2 (ja) * | 2015-02-11 | 2021-12-08 | ディーキン・ユニバーシティー | ＥｐＣＡＭアプタマー及びそのコンジュゲート |
| US10550394B2 (en) * | 2015-03-31 | 2020-02-04 | City Of Hope | Anti-cancer RNA aptamers |
| US11219635B2 (en) | 2016-02-19 | 2022-01-11 | City Of Hope | Bi-specific aptamer |
| WO2019033050A1 (en) | 2017-08-11 | 2019-02-14 | City Of Hope | BISPECIFIC MOLECULE FOR BINDING TO ANTIGEN |
-
2018
- 2018-08-10 EP EP18844104.2A patent/EP3664814A4/en active Pending
- 2018-08-10 CN CN201880066428.2A patent/CN111542326B/zh active Active
- 2018-08-10 CA CA3072575A patent/CA3072575A1/en active Pending
- 2018-08-10 WO PCT/US2018/046343 patent/WO2019033051A1/en not_active Ceased
- 2018-08-10 CN CN202410700060.8A patent/CN118931907A/zh active Pending
- 2018-08-10 KR KR1020207006810A patent/KR20200068647A/ko not_active Ceased
- 2018-08-10 AU AU2018314236A patent/AU2018314236B2/en not_active Expired - Fee Related
- 2018-08-10 JP JP2020507679A patent/JP7382919B2/ja active Active
- 2018-08-10 US US16/637,679 patent/US11427826B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532958A5 (enExample) | ||
| Al-Ghananeem et al. | Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses | |
| JP2022031772A5 (enExample) | ||
| JP5879374B2 (ja) | 筋障害を相殺するための手段と方法 | |
| US12071626B2 (en) | Splice-switching oligonucleotides and methods of use | |
| US11976092B2 (en) | RNA nanostructures, methods of making, and uses thereof | |
| TW201840339A (zh) | 用於肌肉萎縮症之外顯子跳躍寡聚物結合物 | |
| KR20140026396A (ko) | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| JP6847852B2 (ja) | 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害 | |
| CA3090765C (en) | Skin-permeating carrier containing nucleic acid complex and use thereof | |
| US9050373B2 (en) | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same | |
| Karande et al. | Novel approaches for the delivery of biologics to the central nervous system | |
| Al-Ghananeem et al. | Advances in brain targeting and drug delivery of anti-HIV therapeutic agents | |
| Li et al. | Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: inhibiting metastasis and reducing cardiotoxicity | |
| EP4077677A1 (en) | Rna nanoparticle for liver cancer treatment | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| AU2020365736B2 (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| Alkufi et al. | Delivery of nose to brain in the management of cerebral vasospasm in aneurysmal subarachnoid hemorrhage | |
| US20160213696A1 (en) | Treatment of cyr61- and vegf-mediated conditions | |
| US20250255976A1 (en) | Cationic biomaterials ameliorate obesity-associated chronic inflammation and focal adiposity | |
| EP4539831A2 (en) | Targeted nanomedicine for treating lung disorders | |
| JPWO2021231771A5 (enExample) | ||
| Liao | Zhilin Wu1, Chen Chen1Ε, Jiajia Luo1, Jacques RJ Davis1, Bo Zhang2, Liang Tang2, Wei Shi2 & | |
| HK40082399A (en) | Rna nanoparticle for liver cancer treatment |